Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

Lawrence Blonde, Julio Rosenstock, Juan Frias, Andreas L Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stefano Del Prato, Vanita R Aroda, Lawrence Blonde, Julio Rosenstock, Juan Frias, Andreas L Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stefano Del Prato, Vanita R Aroda

Abstract

Objective: In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes uncontrolled with GLP-1 RAs over 26 weeks versus continuing prior GLP-1 RA. A prespecified, 26-week, single-arm extension of LixiLan-G aimed to determine the durability of iGlarLixi efficacy and safety over 52 weeks.

Research design and methods: Participants with type 2 diabetes uncontrolled by GLP-1 RAs (glycated hemoglobin [HbA1c] 7-9% [53-75 mmol/mol]) were initially randomized to switch to iGlarLixi or continue prior GLP-1 RA. Those randomized to iGlarLixi who completed the 26-week primary end point period could continue iGlarLixi open-label treatment over a 26-week extension to assess durability of efficacy and safety.

Results: Glycemic control achieved with iGlarLixi at week 26 (mean HbA1c 6.7% [50 mmol/mol]) was maintained at week 52 (mean HbA1c 6.7% [50 mmol/mol]; mean ± SD change from baseline at week 52: -1.0 ± 0.9% [11 ± 10 mmol/mol]). Proportions of participants reaching HbA1c <7% (53 mmol/mol) with iGlarLixi were similar at week 26 (62%) and 52 (64%), as were those reaching this target without documented symptomatic (<3.0 mmol/L) hypoglycemia (57% and 58%). Safety of iGlarLixi was similar at weeks 26 and 52, with low rates of documented symptomatic hypoglycemia and gastrointestinal events.

Conclusions: The efficacy and safety of iGlarLixi at the end of the 26-week randomized treatment period was maintained over the 26-week extension period in the LixiLan-G trial.

Trial registration: ClinicalTrials.gov NCT02787551.

© 2021 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Glycemic target: HbA1c change from baseline to week 52 (A) and proportion of participants achieving HbA1c <7% (53 mmol/mol) (B) without documented symptomatic (<3.0 mmol/L) hypoglycemia. LS, least squares; No., number.

References

    1. European Medicines Agency . Suliqua summary of product characteristics, 2019. Accessed 12 February 2020. Available from
    1. Sanofi . Soliqua US prescribing information, 2019. Accessed 12 February 2020. Available from
    1. Blonde L, Rosenstock J, Del Prato S, et al. . Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial. Diabetes Care 2019;42:2108–2116
    1. American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S98–S110
    1. Davies MJ, D’Alessio DA, Fradkin J, et al. . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–2701
    1. Hinnen D, Strong J. iGlarLixi: a new once-daily fixed-ratio combination of basal insulin glargine and lixisenatide for the management of type 2 diabetes. Diabetes Spectr 2018;31:145–154
    1. Aroda VR, Rosenstock J, Wysham C, et al. .; LixiLan-L Trial Investigators . Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial [published correction appears in Diabetes Care 2017;40:809]. Diabetes Care 2016;39:1972–1980
    1. Rosenstock J, Aronson R, Grunberger G, et al. .; LixiLan-O Trial Investigators . Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial [published correction appears in Diabetes Care 2017;40:809]. Diabetes Care 2016;39:2026–2035
    1. Blonde L, Raccah D, Lew E, et al. . Treatment intensification in type 2 diabetes: a real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin. Diabetes Ther 2018;9:1169–1184
    1. Feher M, Vega-Hernandez G, Mocevic E, et al. . Effectiveness of liraglutide and lixisenatide in the treatment of type 2 diabetes: real-world evidence from The Health Improvement Network (THIN) database in the United Kingdom. Diabetes Ther 2017;8:417–431
    1. Lee WC, Dekoven M, Bouchard J, Massoudi M, Langer J. Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. Diabetes Obes Metab 2014;16:819–826
    1. Ostawal A, Mocevic E, Kragh N, Xu W. Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther 2016;7:411–438
    1. Montvida O, Klein K, Kumar S, Khunti K, Paul SK. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: a real-world study in 66 583 patients. Diabetes Obes Metab 2017;19:108–117
    1. Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care 2017;40:614–624
    1. Maiorino MI, Chiodini P, Bellastella G, et al. . Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018;20:2309–2313
    1. Maiorino MI, Chiodini P, Bellastella G, et al. . The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2019;154:101–115
    1. Price H, Blüher M, Prager R, Phan TM, Thorsted BL, Schultes B; EXTRA study group . Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab 2018;20:954–962
    1. Watada H, Takami A, Spranger R, Amano A, Hashimoto Y, Niemoeller E. Efficacy and safety of 1:1 fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide in Japanese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: the LixiLan JP-O1 Randomized Clinical Trial. Diabetes Care 2020;43:1249–1257

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever